Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study.

BACKGROUND: In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole. However, increased toxicity was observed. We hypothesized that functional age measures could be used to identify patients at risk fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Li, Daneng, McCall, Linda M., Hahn, Olwen M, Hudis, Clifford A., Cohen, Harvey J., Muss, Hyman B., Jatoi, Aminah, Lafky, Jacqueline M., Ballman, Karla V., Winer, Eric P., Tripathy, Debu, Schneider, Bryan, Barry, William, Dickler, Maura N., Hurria, Arti
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6076849/
https://ncbi.nlm.nih.gov/pubmed/29789969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4828-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados